Wednesday, July 8, 2026

biotech · Type 1 Diabetes Mellitus · Dehydration · HALO

HALOZYME THERAPEUTICS

HALOZYME THERAPEUTICS clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

12390 El Camino Real, San Diego, California 92130, US HQ
2021 Founded
530 Employees
Public company Type
HALO · NYSE Ticker
Company details
Status
Public
HQ
12390 El Camino Real, San Diego, California 92130, US
Founded
2021
Employees
530
Programs
45
Drugs
33
Patents
70
Intelligence · Clinical Programs

HALOZYME THERAPEUTICS projects

16 ClinicalTrials.gov programs sponsored by HALOZYME THERAPEUTICS.

HALOZYME THERAPEUTICS has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial
  2. Atezolizumab

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial
  3. Axumin PET/CT

    HALOZYME THERAPEUTICS, INC.

    Prostate Cancer

    phase 2 small molecule completed

    1 trial
  4. CINRYZE with rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Hereditary Angioedema

    phase 2 mab completed

    1 trial
  5. Eribulin mesylate

    HALOZYME THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial
  6. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial
  7. Humalog

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial
  8. Humalog

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial
  9. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials
  10. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial
  11. Mitomycin C

    HALOZYME THERAPEUTICS, INC.

    Bladder Cancer

    phase 2 small molecule completed

    1 trial
  12. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial
  13. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial
  14. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial
  15. Pegvorhyaluronidase alfa

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial
  16. rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Dermatitis, Allergic Contact

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does HALOZYME THERAPEUTICS have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.